Atopic Dermatitis Drugs Market Size, Share & Trends Analysis Report By Drug Class (Biologics, PDE4 Inhibitors, Corticosteroids, Calcineurin Inhibitors), By Route Of Administration (Topical, Injectable, Oral), By Region, And Segment Forecasts, 2023 - 2030

Report
150 Pages
October 2023
Region: Global
Grand View Research
ID: 5899510

The global atopic dermatitis drugs market size is expected to reach USD 27.68 billion by 2030. It is expected to expand at a CAGR of 8.4% from 2023 to 2030. The market for atopic dermatitis (AD) drugs is expected to witness growth opportunities owing to factors such as the increasing prevalence of atopic dermatitis across the globe, rising awareness, and high demand for treatment. Furthermore, the ongoing launch of innovative products to capture the market is a key strategy adopted by the players to gain market share and maintain their dominance.

A rising number of products in the pipeline, which are highly effective and show fewer adverse effects, is expected to drive the market. For instance, overall, 11 novel drugs indicated for atopic dermatitis are anticipated to be launched in the global market between 2020 and 2029. These include the following drug classes: Janus Kinase (JAK) inhibitors, phosphodiesterase-4 (PDE-4), and interleukin-4 & -13 (IL-4/13). These launches offer improvement in the quality of life and additional choices of treatments to patients with severe and moderate forms of AD.

Support from regulatory authorities, such as the provision of fast-track designation, is anticipated to impel R&D on AD. For instance, Lebrikizumab by Demira, Inc. received a fast-track designation. Moreover, in October 2020, Forte Biosciences, Inc.’s drug FB-401 was granted the fast-track designation by the FDA. Hence, the growing interest of companies in R&D is expected to propel the growth of the market.

An increase in funding for research and development of novel therapies for atopic dermatitis combined with proactive government initiatives will boost regional growth. Collaborations between public and private associations are expected to increase consumer awareness across the globe. For instance, in June 2022, Otsuka Pharmaceutical Co., Ltd. (Otsuka Holdings Co., Ltd.) announced the launch of Moizerto ointment (difamilast) for treating AD in Japan. This ointment is a non-steroidal topical phosphodiesterase type-4 inhibitor.

The Japanese Dermatological Association (JDA) provides AD guidelines for AD in Japan. These guidelines were revised in 2020, specifying diagnostic criteria as well as treatments. For instance, inflammation-related AD is treated using topical corticosteroids and tacrolimus. This facilitates the treatment of patients in a systematic manner, thus improving treatment efficacy.

Atopic Dermatitis Drugs Market Report Highlights

In 2022, biologics dominated the market owing to their higher demand and rising biologics approvals
The injectable route of administration segment held the largest share in 2022 and is likely to maintain its dominance throughout the forecast period
North America dominated the market in 2022 due to the presence of leading market players, increased prevalence of atopic dermatitis, and increased research activities within the region

This product will be delivered within 1-3 business days.

Chapter 1. Methodology and Scope

1.1. Market Segmentation & Scope
1.1.1. Drug Class
1.1.2. Route of Administration
1.1.3. Regional scope
1.1.4. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.5. Market Formulation & Validation
1.6. Model Details
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Drug class outlook
2.2.2. Route of administration outlook
2.2.3. Regional outlook
2.3. Competitive Insights

Chapter 3. Atopic Dermatitis Drugs Market Variables, Trends & Scope

3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Market Dynamics
3.3.1. Market driver analysis
3.3.2. Market restraint analysis
3.4. Atopic Dermatitis Drugs Market Analysis Tools
3.4.1. Industry Analysis - Porter’s
3.4.1.1. Supplier power
3.4.1.2. Buyer power
3.4.1.3. Substitution threat
3.4.1.4. Threat of new entrant
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Technological landscape
3.4.2.3. Economic landscape

Chapter 4. Atopic Dermatitis Drugs: Drug Class Estimates & Trend Analysis

4.1. Atopic Dermatitis Drugs Market: Key Takeaways
4.2. Atopic Dermatitis Drugs Market: Movement & Market Share Analysis, 2022 & 2030
4.3. Corticosteroids
4.3.1. Corticosteroids market estimates and forecasts, 2018 to 2030 (USD Million)
4.4. Calcineurin Inhibitors
4.4.1. Calcineurin inhibitors market estimates and forecasts, 2018 to 2030 (USD Million)
4.5. PDE4 Inhibitors
4.5.1. PDE4 Inhibitors market estimates and forecasts, 2018 to 2030 (USD Million)
4.6. Biologics
4.6.1. Biologics market estimates and forecasts, 2018 to 2030 (USD Million)
4.7. Others
4.7.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Atopic Dermatitis Drugs: Route of Administration Estimates & Trend Analysis

5.1. Atopic Dermatitis Drugs Market: Key Takeaways
5.2. Atopic Dermatitis Drugs Market: Movement & Market Share Analysis, 2022 & 2030
5.3. Topical
5.3.1. Topical market estimates and forecasts, 2018 to 2030 (USD Million)
5.4. Injectable
5.4.1. Injectable market estimates and forecasts, 2018 to 2030 (USD Million)
5.5. Oral
5.5.1. Oral market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Atopic Dermatitis Drugs Market: Regional Estimates & Trend Analysis

6.1. Regional Outlook
6.2. Atopic Dermatitis Drugs Market by Region: Key Marketplace Takeaway
6.3. North America
6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.3.2. U.S.
6.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.3.3. Canada
6.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4. Europe
6.4.1. UK
6.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.2. Germany
6.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.3. France
6.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.4. Italy
6.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.5. Spain
6.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.6. Sweden
6.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.7. Norway
6.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.4.8. Denmark
6.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5. Asia Pacific
6.5.1. Japan
6.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5.2. China
6.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5.3. India
6.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5.4. Australia
6.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5.5. Thailand
6.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.5.6. South Korea
6.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.6. Latin America
6.6.1. Brazil
6.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.6.2. Mexico
6.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.6.3. Argentina
6.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.7. MEA
6.7.1. Saudi Arabia
6.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.7.2. South Africa
6.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.7.3. UAE
6.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)
6.7.4. Kuwait
6.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Million)

Chapter 7. Competitive Landscape

7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Market Participant Categorization
7.2.1. Pfizer Inc.
7.2.1.1. Company overview
7.2.1.2. Financial performance
7.2.1.3. Product benchmarking
7.2.1.4. Strategic initiatives
7.2.2. Sanofi
7.2.2.1. Company overview
7.2.2.2. Financial performance
7.2.2.3. Product benchmarking
7.2.2.4. Strategic initiatives
7.2.3. Regeneron Pharmaceuticals Inc.
7.2.3.1. Company overview
7.2.3.2. Financial performance
7.2.3.3. Product benchmarking
7.2.3.4. Strategic initiatives
7.2.4. LEO Pharma Inc
7.2.4.1. Company overview
7.2.4.2. Financial performance
7.2.4.3. Product benchmarking
7.2.4.4. Strategic initiatives
7.2.5. Otsuka Pharmaceutical Co., Ltd.
7.2.5.1. Company overview
7.2.5.2. Financial performance
7.2.5.3. Product benchmarking
7.2.5.4. Strategic initiatives
7.2.6. AbbVie Inc.
7.2.6.1. Company overview
7.2.6.2. Financial performance
7.2.6.3. Product benchmarking
7.2.6.4. Strategic initiatives
7.2.7. GALDERMA LABORATORIES, L.P.
7.2.7.1. Company overview
7.2.7.2. Financial performance
7.2.7.3. Product benchmarking
7.2.7.4. Strategic initiatives
7.2.8. Dermira, Inc. (Eli Lilly and Company)
7.2.8.1. Company overview
7.2.8.2. Financial performance
7.2.8.3. Product benchmarking
7.2.8.4. Strategic initiatives
7.2.9. Novartis AG
7.2.9.1. Company overview
7.2.9.2. Financial performance
7.2.9.3. Product benchmarking
7.2.9.4. Strategic initiatives
7.2.10. Incyte Corporation
7.2.10.1. Company overview
7.2.10.2. Financial performance
7.2.10.3. Product benchmarking
7.2.10.4. Strategic initiatives

List of Tables

Table 1 List of Abbreviation
Table 2 North America atopic dermatitis drugs market, by drug class, 2018-2030 (USD Million)
Table 3 North America atopic dermatitis drugs market, by route of administration, 2018-2030 (USD Million)
Table 4 North America atopic dermatitis drugs market, by region, 2018-2030 (USD Million)
Table 5 U.S. atopic dermatitis drugs market, by drug class, 2018-2030 (USD Million)
Table 6 U.S. atopic dermatitis drugs market, by route of administration, 2018-2030 (USD Million)
Table 7 Canada atopic dermatitis drugs market, by drug class, 2018-2030 (USD Million)
Table 8 Canada atopic dermatitis drugs market, by route of administration, 2018-2030 (USD Million)
Table 9 Europe atopic dermatitis drugs market, by drug class, 2018-2030 (USD Million)
Table 10 Europe atopic dermatitis drugs market, by route of administration, 2018-2030 (USD Million)
Table 11 Europe atopic dermatitis drugs market, by region, 2018-2030 (USD Million)
Table 12 Germany atopic dermatitis drugs market, by drug class, 2018-2030 (USD Million)
Table 13 Germany atopic dermatitis drugs market, by route of administration, 2018-2030 (USD Million)
Table 14 UK atopic dermatitis drugs market, by drug class, 2018-2030 (USD Million)
Table 15 UK atopic dermatitis drugs market, by route of administration, 2018-2030 (USD Million)
Table 16 France atopic dermatitis drugs market, by drug class, 2018-2030 (USD Million)
Table 17 France atopic dermatitis drugs market, by route of administration, 2018-2030 (USD Million)
Table 18 Italy atopic dermatitis drugs market, by drug class, 2018-2030 (USD Million)
Table 19 Italy atopic dermatitis drugs market, by route of administration, 2018-2030 (USD Million)
Table 20 Spain atopic dermatitis drugs market, by drug class, 2018-2030 (USD Million)
Table 21 Spain atopic dermatitis drugs market, by route of administration, 2018-2030 (USD Million)
Table 22 Sweden atopic dermatitis drugs market, by drug class, 2018-2030 (USD Million)
Table 23 Sweden atopic dermatitis drugs market, by route of administration, 2018-2030 (USD Million)
Table 24 Norway atopic dermatitis drugs market, by drug class, 2018-2030 (USD Million)
Table 25 Norway atopic dermatitis drugs market, by route of administration, 2018-2030 (USD Million)
Table 26 Denmark atopic dermatitis drugs market, by drug class, 2018-2030 (USD Million)
Table 27 Denmark atopic dermatitis drugs market, by route of administration, 2018-2030 (USD Million)
Table 28 Asia Pacific atopic dermatitis drugs market, by drug class, 2018-2030 (USD Million)
Table 29 Asia Pacific atopic dermatitis drugs market, by route of administration, 2018-2030 (USD Million)
Table 30 Asia Pacific atopic dermatitis drugs market, by region, 2018-2030 (USD Million)
Table 31 China atopic dermatitis drugs market, by drug class, 2018-2030 (USD Million)
Table 32 China atopic dermatitis drugs market, by route of administration, 2018-2030 (USD Million)
Table 33 Japan atopic dermatitis drugs market, by drug class, 2018-2030 (USD Million)
Table 34 Japan atopic dermatitis drugs market, by route of administration, 2018-2030 (USD Million)
Table 35 India atopic dermatitis drugs market, by drug class, 2018-2030 (USD Million)
Table 36 India atopic dermatitis drugs market, by route of administration, 2018-2030 (USD Million)
Table 37 Thailand atopic dermatitis drugs market, by drug class, 2018-2030 (USD Million)
Table 38 Thailand atopic dermatitis drugs market, by route of administration, 2018-2030 (USD Million)
Table 39 South Korea atopic dermatitis drugs market, by drug class, 2018-2030 (USD Million)
Table 40 South Korea atopic dermatitis drugs market, by route of administration, 2018-2030 (USD Million)
Table 41 Latin America atopic dermatitis drugs market, by drug class, 2018-2030 (USD Million)
Table 42 Latin America atopic dermatitis drugs market, by route of administration, 2018-2030 (USD Million)
Table 43 Latin America atopic dermatitis drugs market, by region, 2018-2030 (USD Million)
Table 44 Brazil atopic dermatitis drugs market, by drug class, 2018-2030 (USD Million)
Table 45 Brazil atopic dermatitis drugs market, by route of administration, 2018-2030 (USD Million)
Table 46 Mexico atopic dermatitis drugs market, by drug class, 2018-2030 (USD Million)
Table 47 Mexico atopic dermatitis drugs market, by route of administration, 2018-2030 (USD Million)
Table 48 Argentina atopic dermatitis drugs market, by drug class, 2018-2030 (USD Million)
Table 49 Argentina atopic dermatitis drugs market, by route of administration, 2018-2030 (USD Million)
Table 50 Middle East and Africa atopic dermatitis drugs market, by drug class, 2018-2030 (USD Million)
Table 51 Middle East and Africa atopic dermatitis drugs market, by route of administration, 2018-2030 (USD Million)
Table 52 Middle East and Africa atopic dermatitis drugs market, by region, 2018-2030 (USD Million)
Table 53 South Africa atopic dermatitis drugs market, by drug class, 2018-2030 (USD Million)
Table 54 South Africa atopic dermatitis drugs market, by route of administration, 2018-2030 (USD Million)
Table 55 Saudi Arabia atopic dermatitis drugs market, by drug class, 2018-2030 (USD Million)
Table 56 Saudi Arabia atopic dermatitis drugs market, by route of administration, 2018-2030 (USD Million)
Table 57 UAE atopic dermatitis drugs market, by drug class, 2018-2030 (USD Million)
Table 58 UAE atopic dermatitis drugs market, by route of administration, 2018-2030 (USD Million)
Table 59 Kuwait atopic dermatitis drugs market, by drug class, 2018-2030 (USD Million)
Table 60 Kuwait atopic dermatitis drugs market, by route of administration, 2018-2030 (USD Million)

List of Figures

Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Atopic dermatitis drugs: Market outlook
Fig. 9 Atopic dermatitis drugs: Competitive insights
Fig. 10 Parent market outlook
Fig. 11 Related/ancillary market outlook
Fig. 12 Penetration and growth prospect mapping
Fig. 13 Industry value chain analysis
Fig. 14 Atopic dermatitis drugs market driver impact
Fig. 15 Atopic dermatitis drugs market restraint impact
Fig. 16 Atopic dermatitis drugs market strategic initiatives analysis
Fig. 17 Atopic dermatitis drugs market: Drug class movement analysis
Fig. 18 Atopic dermatitis drugs market: Drug class outlook and key takeaways
Fig. 19 Corticosteroids market estimates and forecasts, 2018-2030 (USD Million)
Fig. 20 Calcineurin inhibitors market estimates and forecasts, 2018-2030 (USD Million)
Fig. 21 PDE4 inhibitors market estimates and forecasts, 2018-2030 (USD Million)
Fig. 22 Biologics market estimates and forecasts, 2018-2030 (USD Million)
Fig. 23 Others market estimates and forecasts, 2018-2030 (USD Million)
Fig. 24 Atopic dermatitis drugs market: Route of administration movement analysis
Fig. 25 Atopic dermatitis drugs market: Route of administration outlook and key takeaways
Fig. 26 Topical market estimates and forecasts, 2018-2030 (USD Million)
Fig. 27 Injectable market estimates and forecasts, 2018-2030 (USD Million)
Fig. 28 Oral market estimates and forecasts, 2018-2030 (USD Million)
Fig. 29 Global atopic dermatitis drugs market: Regional movement analysis
Fig. 30 Global atopic dermatitis drugs market: Regional outlook and key takeaways
Fig. 31 North America market estimates and forecasts, 2018-2030 (USD Million)
Fig. 32 U.S. market estimates and forecasts, 2018-2030 (USD Million)
Fig. 33 Canada market estimates and forecasts, 2018-2030 (USD Million)
Fig. 34 Europe market estimates and forecasts, 2018-2030 (USD Million)
Fig. 35 UK market estimates and forecasts, 2018-2030 (USD Million)
Fig. 36 Germany market estimates and forecasts, 2018-2030 (USD Million)
Fig. 37 France market estimates and forecasts, 2018-2030 (USD Million)
Fig. 38 Italy market estimates and forecasts, 2018-2030 (USD Million)
Fig. 39 Spain market estimates and forecasts, 2018-2030 (USD Million)
Fig. 40 Sweden market estimates and forecasts, 2018-2030 (USD Million)
Fig. 41 Norway market estimates and forecasts, 2018-2030 (USD Million)
Fig. 42 Denmark market estimates and forecasts, 2018-2030 (USD Million)
Fig. 43 Asia Pacific market estimates and forecasts, 2018-2030 (USD Million)
Fig. 44 Japan market estimates and forecasts, 2018-2030 (USD Million)
Fig. 45 China market estimates and forecasts, 2018-2030 (USD Million)
Fig. 46 India market estimates and forecasts, 2018-2030 (USD Million)
Fig. 47 Australia market estimates and forecasts, 2018-2030 (USD Million)
Fig. 48 Thailand market estimates and forecasts, 2018-2030 (USD Million)
Fig. 49 South Korea market estimates and forecasts, 2018-2030 (USD Million)
Fig. 50 Latin America market estimates and forecasts, 2018-2030 (USD Million)
Fig. 51 Brazil market estimates and forecasts, 2018-2030 (USD Million)
Fig. 52 Mexico market estimates and forecasts, 2018-2030 (USD Million)
Fig. 53 Argentina market estimates and forecasts, 2018-2030 (USD Million)
Fig. 54 Middle East and Africa. market estimates and forecasts, 2018-2030 (USD Million)
Fig. 55 Saudi Arabia market estimates and forecasts, 2018-2030 (USD Million)
Fig. 56 South Africa market estimates and forecasts, 2018-2030 (USD Million)
Fig. 57 UAE market estimates and forecasts, 2018-2030 (USD Million)
Fig. 58 Kuwait market estimates and forecasts, 2018-2030 (USD Million)

Companies Mentioned

Pfizer Inc.
Sanofi
Regeneron Pharmaceuticals Inc.
LEO Pharma Inc
Otsuka Pharmaceutical Co., Ltd.
AbbVie Inc.
GALDERMA LABORATORIES, L.P.
Dermira, Inc. (Eli Lilly and Company)
Novartis AG
Incyte Corporation

Methodology

LOADING...

Table Information

Report Attribute	Details
No. of Pages	150
Published	October 2023
Forecast Period	2022 - 2030
Estimated Market Value ( USD ) in 2022	$ 14.19 Billion
Forecasted Market Value ( USD ) by 2030	$ 27.68 Billion
Compound Annual Growth Rate	8.4%
Regions Covered	Global
No. of Companies Mentioned	10

PURCHASE OPTIONS

Single User License PDF

1 - 5 User License PDF

Enterprise License PDF

need a quote ?

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€5752EUR$5,950USD£4,941GBP
1 - 5 USER LICENSE PDF	The product is a PDF.	This is a 1-5 user license, allowing up to five users have access to the product.	€6719EUR$6,950USD£5,771GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€8653EUR$8,950USD£7,432GBP

Atopic Dermatitis Drugs Market Report Highlights

Table of Contents

Companies Mentioned

Methodology

Table Information

Related Topics

Related Reports

Global Atopic Dermatitis Drugs Market by Drug Class (Biologics, Calcineurin Inhibitors, Corticosteroids), Route of Administration (Injectable ROA, Oral ROA, Tropical ROA) - Forecast 2024-2030

Global Atopic Dermatitis Clinical Trials Market Size, Share & Trends Analysis Report by Molecule Type (Small molecules, Large Molecules), Study Designs, Study Phase, Region, and Segment Forecasts, 2024-2030

Atopic Dermatitis Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F

Global Atopic Dermatitis Drugs Market (2023-2028) Competitive Analysis, Impact of Covid-19, Ansoff Analysis

Global Atopic Dermatitis Clinical Trials Market Analysis & Forecast to 2024-2034: Market By Phase; By Molecule Type; By Study Design; and By Region